SEC Form 4 · accession 0001209191-18-028449
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dietmar Berger
Officer — Global Head of R&D
Period of report
May 7, 2018
Accepted (ET)
May 7, 2018 · 7:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 7, 2018 | A | 50,000 | $0.00 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $42.05 | May 7, 2018 | A | 85,000 | A | — | May 6, 2025 | Common Stock | 85,000 | 85,000 | D |
Explanation of responses
- F125% of the shares subject to restricted stock units vest on May 7, 2019 and the remaining shares vest in equal annual installments over the following 3 years.
- F225% of the shares subject to the option vest on May 7, 2019 and the remaining shares vest in equal monthly installments over the following 36 months.